Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

102.50EUR
18 Jul 2019
Change (% chg)

€0.60 (+0.59%)
Prev Close
€101.90
Open
€101.10
Day's High
€102.90
Day's Low
€101.10
Volume
60,591
Avg. Vol
118,776
52-wk High
€107.40
52-wk Low
€68.60

Latest Key Developments (Source: Significant Developments)

DiaSorin targets 'mid-to-high single-digit' revenue growth in 2019-2022
Monday, 10 Jun 2019 12:19pm EDT 

June 10 (Reuters) - Italy's DiaSorin says::SEES "MID-TO-HIGH SINGLE-DIGIT" REVENUE GROWTH UNDER NEW 2019-2022 PLAN, BASED ON 2018 CURRENT EXCHANGE RATES.SEES EBITDA MARGIN IN LINE WITH 2018 UNDER NEW BUSINESS PLAN.CUMULATED CASH-FLOW IN 2019-2022 OF 700-750 MILLION EUROS.CONFIRMS AIM TO DEVELOP 5-6 NEW TESTS IN IMMUNODIAGNOSTICS AS WELL AS MOLECULAR DIAGNOSTICS PER YEAR DURING 2019-2022 PERIOD.  Full Article

Qiagen Expands Collaboration With Diasorin On Lyme Disease Research
Wednesday, 5 Jun 2019 01:30am EDT 

June 5 (Reuters) - Qiagen ::QIAGEN AND DIASORIN COLLABORATE ON NOVEL QUANTIFERON-BASED TEST WITH BREAKTHROUGH POTENTIAL FOR EARLIER DETECTION OF LYME DISEASE.COMPANIES PLAN MULTI-SITE CLINICAL VALIDATIONS DURING 2020 LYME DISEASE SEASON.REGULATORY SUBMISSIONS EXPECTED AT END OF SAME YEAR IN UNITED STATES AND EUROPE.  Full Article

Diasorin And Qiagen Expand Collaboration For QuantiFERON Technology
Wednesday, 5 Jun 2019 01:25am EDT 

June 5 (Reuters) - DiaSorin SpA ::SAYS DIASORIN AND QIAGEN ANNOUNCE EXPANSION OF COLLABORATION FOR QUANTIFERON TECHNOLOGY.NEW TEST BASED ON QUANTIFERON TECHNOLOGY FOR DIAGNOSIS OF LYME DISEASE WILL BE USED ON LIAISON PLATFORMS.  Full Article

Diasorin Launches VZV Direct Molecular Test In United States
Wednesday, 29 May 2019 09:04am EDT 

May 29 (Reuters) - DiaSorin SpA ::LAUNCHES VZV DIRECT MOLECULAR TEST IN UNITED STATES.RECEIVES FDA CLEARANCE FOR ITS VZV DIRECT ASSAY FOR USE WITH CEREBROSPINAL FLUID (CSF) SAMPLES.DIAGNOSTIC TEST ENABLES DETECTION OF VARICELLA-ZOSTER VIRUS (VZV) DNA FROM CSF AND SERVES AS TOOL TO AID IN DIAGNOSIS OF MENINGITIS AND ENCEPHALITIS.  Full Article

Diasorin SpA Q1 Net Profit Up At EUR 40.4 Mln
Thursday, 9 May 2019 07:11am EDT 

May 9 (Reuters) - DiaSorin SpA ::Q1 REVENUE EUR 170.8 MILLION VERSUS EUR 164.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 40.4 MILLION VERSUS EUR 38.3 MILLION YEAR AGO.  Full Article

Diasorin Gets Authorization For Marketing OF Vitamin B12 And Folate Quantification Tests In Europe
Wednesday, 3 Apr 2019 04:30am EDT 

April 3 (Reuters) - DiaSorin SpA ::GETS AUTHORIZATION FOR MARKETING IN EUROPE OF TESTS FOR QUANTIFICATION OF VITAMIN B12 AND FOLATE TO SUPPORT DIAGNOSIS AND TREATMENT OF ANEMIA.  Full Article

DiaSorin Proposes Ordinary Dividend Of EUR 0.90 /shr
Thursday, 14 Mar 2019 09:13am EDT 

March 14 (Reuters) - DiaSorin SpA ::PROPOSED ORDINARY DIVIDEND OF EUR 0.90 PER SHARE.  Full Article

DiaSorin FY Net Profit Up At EUR 158.1 Mln
Thursday, 14 Mar 2019 09:13am EDT 

March 14 (Reuters) - DiaSorin SpA ::FY NET PROFIT EUR 158.1 MILLION, UP 13.0% VERSUS YEAR AGO.FY REVENUES: € 669.2 MILLION, +5.0% (+7.7% AT CER).2019 GUIDANCE AT CONSTANT EXCHANGE RATE FOR EBITDA MARGIN: COMPARABLE TO 2018 EBITDA MARGIN RESULT.SEES REVENUES GROWTH BETWEEN 5.0% AND 8.0% IN 2019 AT CONSTANT EXCHANGE RATES.CAPITAL MARKET DAY: ON JUNE 11, 2019 IN TURIN.  Full Article

DiaSorin Launches 3 New Primer Pairs For Use In Molecular Testing Of Lung Infection
Friday, 21 Dec 2018 05:37am EST 

Dec 21 (Reuters) - DiaSorin SpA ::LAUNCHES 3 NEW PRIMER PAIRS FOR USE IN MOLECULAR TESTING.SPECIFIC TARGETS ARE LEGIONELLA SPECIES, CHLAMYDOPHILA PNEUMONIAE AND MYCOPLASMA PNEUMONIAE.ALL THREE TEST TARGETS MAY INFECT LUNGS.  Full Article

Diasorin Shares Included In FTSE MIB Index As Of Dec 4
Tuesday, 4 Dec 2018 01:50am EST 

Dec 4 (Reuters) - DiaSorin SpA ::ANNOUNCES THAT ITS SHARES ARE INCLUDED IN THE FTSE MIB INDEX OF MILAN STOCK EXCHANGE AS OF DEC 4.  Full Article

CORRECTED-DIARY - Italy to June 30

(Changes dates of two-day energy conference in Rome to May 29-30 from May 28-29) Inclusion of diary items does not necessarily mean that Reuters will file a story based on the event.